Security key
G1933S101
CASI Pharmaceuticals, Inc. - Ordinary Shares (CASIF)
CUSIP: G1933S101
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Ordinary Shares
- Total 13F shares
- 1,251,879
- Total 13F value
- $1,063,851
- Share change
- -1,354,964
- SEC-reported price per share
- $0.85
- Number of holders
- 16
- Value change
- -$2,036,507
- Number of buys
- 4
- Number of sells
- 11
- Shares outstanding
- 40,791,726
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
16
Top holders
10
CASIF full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
CASI Pharmaceuticals, Inc. SEC filings
CASI Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP G1933S101
Recent filing periods:
Ownership snapshot
Top reported holders of CASIF - CASI Pharmaceuticals, Inc. - Ordinary Shares (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Panacea Innovation Ltd
Disclosed value leader
Panacea Innovation Ltd
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G
13F
Lead comparable stake: 22%
13D/G row: Panacea Innovation Ltd
Showing 1-6 of 15 holder rows.
Quick read
Panacea Innovation Ltd leads the comparable SEC ownership view at 22%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Panacea Innovation Ltd's linked filing trail.
Comparable ownership
Top 5
Panacea Innovation Ltd
22%
James Huang
14%
Zhenfeng M. Chen
11%
Venrock Healthcare Capital Partne...
9.2%
SPARKLE BYTE LTD
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Panacea Innovation Ltd |
13D/G
James Huang
|
22%
|
$4,698,042
4,651,527 shares
|
+$999,856 | 16 Dec 2025 |
| James Huang |
13D/G
|
14%
|
$3,177,509
2,161,571 shares
|
$0 | 30 Jun 2025 |
| Zhenfeng M. Chen |
13D/G
Chen Zhenfeng
|
11%
|
$4,150,370
2,255,636 shares
|
$0 | 30 Sep 2025 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
9.2%
|
$2,066,749
1,987,259 shares
|
$0 | 31 Dec 2025 |
| SPARKLE BYTE LTD |
13D/G
|
5%
|
$775,088
1,019,852 shares
|
$0 | 30 Sep 2025 |
| Ho Chi Sing |
13D/G
Zhou Quan
|
4.8%
|
$754,405
992,638 shares
|
$0 | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
16
Shares
1,251,879
Rows available
16
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
21
Q4 2025 holders
16
Holder diff
-5
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend